Mark Brister - Net Worth and Insider Trading
Mark Brister Net Worth
The estimated net worth of Mark Brister is at least $23 Million dollars as of 2024-05-10. Mark Brister is the VP Advanced Development Teams of DexCom Inc and owns about 175,472 shares of DexCom Inc (DXCM) stock worth over $22 Million. Mark Brister is also the Chief Technology Officer of Obalon Therapeutics Inc and owns about 12,955 shares of Obalon Therapeutics Inc (OBLN) stock worth over $39,513. Details can be seen in Mark Brister's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Brister has not made any transactions after 2019-08-06 and currently still holds the listed stock(s).
Transaction Summary of Mark Brister
Mark Brister Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Brister owns 3 companies in total, including Obalon Therapeutics Inc (OBLN) , DexCom Inc (DXCM) , and Reshape Lifesciences Inc (RSLS) .
Click here to see the complete history of Mark Brister’s form 4 insider trades.
Insider Ownership Summary of Mark Brister
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| OBLN | Obalon Therapeutics Inc | 2020-01-24 | Chief Technology Officer |
| DXCM | DexCom Inc | 2006-05-02 | VP & Advanced Development Teams |
| RSLS | Reshape Lifesciences Inc | 2016-10-05 | VP of Research and Development |
Mark Brister Latest Holdings Summary
Mark Brister currently owns a total of 2 stocks. Among these stocks, Mark Brister owns 175,472 shares of DexCom Inc (DXCM) as of May 2, 2006, with a value of $22 Million and a weighting of 99.82%. Mark Brister also owns 12,955 shares of Obalon Therapeutics Inc (OBLN) as of August 6, 2019, with a value of $39,513 and a weighting of 0.18%.
Latest Holdings of Mark Brister
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| DXCM | DexCom Inc | 2006-05-02 | 175,472 | 128.19 | 22,493,756 |
| OBLN | Obalon Therapeutics Inc | 2019-08-06 | 12,955 | 3.05 | 39,513 |
Holding Weightings of Mark Brister
Mark Brister Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Brister has made a total of 0 transactions in DexCom Inc (DXCM) over the past 5 years. The most-recent trade in DexCom Inc is the sale of 800,000 shares on May 2, 2006, which brought Mark Brister around $1 Million.
According to the SEC Form 4 filings, Mark Brister has made a total of 1 transactions in Obalon Therapeutics Inc (OBLN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Obalon Therapeutics Inc is the acquisition of 1,667 shares on August 6, 2019, which cost Mark Brister around $20,000.
Insider Trading History of Mark Brister
- 1
Mark Brister Trading Performance
GuruFocus tracks the stock performance after each of Mark Brister's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Brister is -43.38%. GuruFocus also compares Mark Brister's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Brister within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Brister's insider trading performs compared to the benchmark.
Performance of Mark Brister
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -43.38 | | | | | |
| Relative Return to S&P 500(%) | -46.74 | | | | | |
Mark Brister Ownership Network
Mark Brister Owned Company Details
What does Obalon Therapeutics Inc do?
Who are the key executives at Obalon Therapeutics Inc?
Mark Brister is the Chief Technology Officer of Obalon Therapeutics Inc. Other key executives at Obalon Therapeutics Inc include director & President & CEO & Exec Chairman Andrew P Rasdal , Chief Financial Officer Nooshin Hussainy , and Chief Retail Officer Robert J Macdonald .
Obalon Therapeutics Inc (OBLN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Obalon Therapeutics Inc (OBLN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Obalon Therapeutics Inc (OBLN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Obalon Therapeutics Inc (OBLN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Obalon Therapeutics Inc Insider Transactions
Mark Brister Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Brister. You might contact Mark Brister via mailing address: C/o Dexcom, Inc., 5555 Oberlin Drive, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
